Stockscreener 앱 받기
0.49
3.73%
-0.019
시간 외 거래:
.43
-0.06
-12.24%
Entero Therapeutics Inc 주식(ENTO)의 최신 뉴스
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Entero Therapeutics Delays 10-K Filing - TipRanks
Celiac Disease Pipeline: Pioneering Progress with 25+ Leading - openPR.com
Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener
Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN
Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance
Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail
Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail
Hogs Close with Weakness on Thursday - The Globe and Mail
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail
This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail
European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail
The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Celiac Disease Market Expected to Experience Major Growth - openPR
Significant Contract News Sends Energy Services Company Higher - The Globe and Mail
How Nvidia (NASDAQ:NVDA) Stayed One Step Ahead in the AI Race - The Globe and Mail
Super Micro's International Presence Makes It a Winning Stock - The Globe and Mail
Vicarious Surgical Names Sarah Romano as Finance Chief - MPO-mag
3 Artificial Intelligence (AI) Stocks That Can Weather President Trump's Tariff Storm - The Globe and Mail
Vicarious Surgical appoints Sarah Romano as CFO - MedTech Dive
Can Nvidia’s Stock Keep Climbing as Foxconn Bets Big on AI? - The Globe and Mail
Greif Named 2025 Gallup Exceptional Workplace Award Winner - The Globe and Mail
Vicarious Surgical names Sarah Romano as new CFO By Investing.com - Investing.com Australia
Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer - citybiz
Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer - Business Wire
3 Ways Tech Investors Can Navigate the Artificial Intelligence (AI) Sector Tumble - The Globe and Mail
Stocks Mixed as President Trump Ramps Up Tariffs on Canada - The Globe and Mail
Goldman Sachs: Buy These 2 ‘Rising Star’ Stocks in 2025 - The Globe and Mail
Where Will Coca-Cola Stock Be in 5 Years? - The Globe and Mail
Reflecting On Auto Parts Retailer Stocks’ Q4 Earnings: AutoZone (NYSE:AZO) - The Globe and Mail
Onconetix taps industry veteran as executive chairman amid CEO resignationCincinnati Business Courier - Cincinnati Business Courier
Onconetix names new executive chairman, appoints board member - Investing.com
iHeartMedia (IHRT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Entero Therapeutics Appoints Richard Paolone as CEO - citybiz
AzurRx BioPharma Receives Approximately $550,000 for its 2020 CIR (French Research Tax Credit) - Marketscreener.com
Entero Therapeutics names Richard Paolone interim CEO - MSN
Entero Therapeutics Appoints Richard Paolone as Interim CEO - TipRanks
Entero Therapeutics names Richard Paolone interim CEO By Investing.com - Investing.com South Africa
Entero Therapeutics Names Richard Paolone Interim CEO - MarketWatch
Entero Therapeutics Names Richard Paolone Interim CEO -February 14, 2025 at 04:25 pm EST - Marketscreener.com
Strategic Leadership Shift: M&A Expert Takes Helm at Entero TherapeuticsKey Details Revealed - StockTitan
Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - Marketscreener.com
Entero Therapeutics Inc (ENTO) Shares Soar Above 1-Year High - The News Heater
Entero Therapeutics Appoints Three New Board Members - citybiz
Entero Therapeutics Gets $2 Million Revolving Loan, Appoints 3 New Board Members - Marketscreener.com
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members - The Manila Times
Entero Therapeutics Secures $2 Million Loan and Appoints New Board Members - Nasdaq
Entero Therapeutics, Inc. Announces Board Changes -February 07, 2025 at 03:22 pm EST - Marketscreener.com
Entero Therapeutics Announces Board of Directors Restructuring - TipRanks
AzurRx BioPharma Announces Results of Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency - Marketscreener.com
Analyst Insights: Apple, Amazon, and ARC Resources Lead Buy Ratings - The Globe and Mail
Entero Therapeutics faces Nasdaq delisting over meeting lapse By Investing.com - Investing.com Australia
Entero Therapeutics faces Nasdaq delisting over meeting lapse - Investing.com
0.48%
자본화:
|
볼륨(24시간):